Lifecore Biomedical
LFCR
93 hedge funds and large institutions have $306M invested in Lifecore Biomedical in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 33 increasing their positions, 31 reducing their positions, and 18 closing their positions.
7% more capital invested
Capital invested by funds: $288M → $306M (+$18.8M)
2.04% more ownership
Funds ownership: 90.91% → 92.95% (+2%)
6% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
11% less funds holding
Funds holding: 104 → 93 (-11)
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$7.08M |
| 2 |
LPAM
Legion Partners Asset Management
Los Angeles,
California
|
+$6.03M |
| 3 |
HFA
Harbert Fund Advisors
Birmingham,
Alabama
|
+$1.26M |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.1M |
| 5 |
PRCP
Pacific Ridge Capital Partners
Lake Oswego,
Oregon
|
+$871K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
-$6.29M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$2.42M |
| 3 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$2.03M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.43M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$1.05M |
LFCR Hedge Fund Activity: Q4 2019 in Review
93 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2019, worth a combined $306M — up 6.5% from $288M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of LFCR and 7 opened new positions — a net loss of 11 holders — while 31 trimmed existing stakes and 33 added.
The largest buyer was Russell Investments Group, adding an estimated $7.08M. The largest seller was NWQ Investment Management Company, cutting an estimated $6.29M.
- 93 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2019, down from 104 in Q3 2019.
- Funds reported $306M of Lifecore Biomedical stock for Q4 2019, up 6.5% quarter-over-quarter.
- 7 funds opened new Lifecore Biomedical positions in Q4 2019 and 18 closed out, a net change of -11 holders.
- The largest Lifecore Biomedical buyer in Q4 2019 was Russell Investments Group, an estimated $7.08M added.
- The largest Lifecore Biomedical seller in Q4 2019 was NWQ Investment Management Company, an estimated $6.29M sold.
Based on aggregated 13F filings for Q4 2019.